Skip to contentA
Alnylam Pharmaceuticals, Inc.
A
ALNYAlnylam Pharmaceuticals, Inc. Source filing unavailable
Q3 2013 · —
Revenue—
Net Income-$29.69M-$29.69MN/M vs Q3 2012 EPS Diluted-$0.48-$0.48N/M vs Q3 2012 Operating Income-$32,234,000N/M Operating Cash Flowderived-$21,715,000N/M Free Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
-$22,665,000
N/M